| answer text |
<p>Standard care for type 1 diabetes involves regularly measuring blood glucose levels
by self-monitoring, blood testing, or by using a continuous glucose monitor, real-time
or intermittently scanned.</p><p>The NHS Long Term Plan committed that 20% of people
with type 1 diabetes would benefit from life changing flash glucose monitors. Data
to quarter three of 2022/23 shows that 73% of people with type 1 diabetes were prescribed
flash glucose monitoring, against the 20% target.</p><p>In March 2023 the National
Institute for Health and Care Excellence (NICE) recommended that insulin dependent
patients with type 2 diabetes should also benefit from flash or continuous glucose
monitoring devices. We are now starting to see a growth in prescribing within the
type 2 diabetes patient group.</p><p>On 19 December 2023 the NICE published its final
recommendation on the hybrid closed loop system. The NICE has agreed with NHS England
that all children and young people, women who are pregnant or planning a pregnancy,
and those people who already have an insulin pump will be the first to be offered
a hybrid closed loop system, as part of a five-year roll-out plan. Access to hybrid
closed loop systems will be through a five-year phased roll out, in line with NHS
England’s implementation plans.</p>
|
|
